Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) [Phase 1, Phase 2]

View source ↗

Summary

The document reports a personalized antisense oligonucleotide therapy for a single patient with CHCHD10-related amyotrophic lateral sclerosis (nL18576). The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Personalized antisense oligonucleotide therapy (nL18576)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING